ATE304009T1 - Neue benzotriazole mit entzündungshemmender wirkung - Google Patents
Neue benzotriazole mit entzündungshemmender wirkungInfo
- Publication number
- ATE304009T1 ATE304009T1 AT02252153T AT02252153T ATE304009T1 AT E304009 T1 ATE304009 T1 AT E304009T1 AT 02252153 T AT02252153 T AT 02252153T AT 02252153 T AT02252153 T AT 02252153T AT E304009 T1 ATE304009 T1 AT E304009T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitor
- new
- definitions
- heterocyclyl
- cycloalkyl
- Prior art date
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- 150000001565 benzotriazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 4
- 102000015696 Interleukins Human genes 0.000 abstract 2
- 108010063738 Interleukins Proteins 0.000 abstract 2
- 102000043136 MAP kinase family Human genes 0.000 abstract 2
- 108091054455 MAP kinase family Proteins 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 abstract 1
- 229940124790 IL-6 inhibitor Drugs 0.000 abstract 1
- 102000004890 Interleukin-8 Human genes 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000002456 anti-arthritic effect Effects 0.000 abstract 1
- 230000001088 anti-asthma Effects 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 230000003356 anti-rheumatic effect Effects 0.000 abstract 1
- 230000000767 anti-ulcer Effects 0.000 abstract 1
- 239000000924 antiasthmatic agent Substances 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229960002708 antigout preparations Drugs 0.000 abstract 1
- 239000003435 antirheumatic agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 239000002423 protozoacide Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000002537 thrombolytic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28133101P | 2001-04-04 | 2001-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE304009T1 true ATE304009T1 (de) | 2005-09-15 |
Family
ID=23076827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02252153T ATE304009T1 (de) | 2001-04-04 | 2002-03-26 | Neue benzotriazole mit entzündungshemmender wirkung |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6664395B2 (de) |
| EP (1) | EP1247810B1 (de) |
| JP (1) | JP3832646B2 (de) |
| AT (1) | ATE304009T1 (de) |
| BR (1) | BR0201087A (de) |
| CA (1) | CA2379903C (de) |
| DE (1) | DE60205974T2 (de) |
| ES (1) | ES2247271T3 (de) |
| MX (1) | MXPA02003454A (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0207297A (pt) | 2001-02-15 | 2005-04-19 | King Pharmaceuticals Inc | Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo |
| US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| DE60227794D1 (de) * | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| US6949652B2 (en) | 2002-08-30 | 2005-09-27 | Pfizer, Inc. | Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine |
| US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
| US7037923B2 (en) | 2002-08-30 | 2006-05-02 | Pfizer, Inc. | Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
| US7012143B2 (en) | 2002-08-30 | 2006-03-14 | Dombroski Mark A | Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
| PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
| US20060122240A1 (en) * | 2002-11-05 | 2006-06-08 | Arena Pharmaceuticals, Inc. | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof |
| ES2264795T3 (es) | 2003-02-14 | 2007-01-16 | Pfizer Products Inc. | Triazolo-piridinas como compuestos antiinflamatorios. |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| WO2004099127A1 (en) * | 2003-05-07 | 2004-11-18 | Novo Nordisk A/S | Novel compounds as kinase inhibitors |
| JP4939220B2 (ja) | 2003-05-15 | 2012-05-23 | アークル インコーポレイテッド | ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体 |
| BRPI0417674A (pt) * | 2003-12-18 | 2007-03-20 | Pfizer Prod Inc | método para tratar a inflamação aguda em animais, com inibidores de quinase map p38 |
| US7829560B2 (en) * | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
| WO2006044869A1 (en) * | 2004-10-19 | 2006-04-27 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| PE20070341A1 (es) * | 2005-07-29 | 2007-04-13 | Wyeth Corp | Derivados de pirrol como moduladores del receptor de progesterona |
| PE20070404A1 (es) * | 2005-07-29 | 2007-05-10 | Wyeth Corp | Compuestos derivados de cianopirrol-sulfonamida como moduladores del receptor de progesterona |
| PE20070182A1 (es) * | 2005-07-29 | 2007-03-06 | Wyeth Corp | Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona |
| MX2010010781A (es) * | 2008-04-04 | 2010-12-14 | Lilly Co Eli | 3-indazolil-4-piridilisotiazoles. |
| EP2307411B1 (de) * | 2008-06-20 | 2014-01-01 | Bristol-Myers Squibb Company | Als kinaseinhibitoren geeignete triazolopyridinverbindungen |
| CA2744713A1 (en) * | 2008-12-05 | 2010-06-10 | Arqule, Inc. | Raf inhibitors and their uses |
| WO2010141360A1 (en) * | 2009-06-05 | 2010-12-09 | Merck Sharp & Dohme Corp. | Biaryl benzotriazole derivatives |
| US20160194336A1 (en) * | 2012-12-17 | 2016-07-07 | Allinky Biopharma | P38 mapk inhibitors for the treatment of inflammatory diseases |
| CN105189447B (zh) * | 2013-06-25 | 2017-12-05 | 组合化学工业株式会社 | 制造硝基苯化合物的方法 |
| CN105481863B (zh) * | 2015-12-09 | 2018-11-02 | 科贝源(北京)生物医药科技有限公司 | 2-甲基-6-(4-甲基苯磺酰基)-1,4,5,6-四氢咪唑并[4,5-d][1]苯并氮杂*的合成方法 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| IL271149B2 (en) * | 2017-06-14 | 2024-05-01 | Trevena Inc | Compounds for modulating s1p1 activity and methods of using the same |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP2021501130A (ja) | 2017-10-05 | 2021-01-14 | フルクラム セラピューティクス，インコーポレイテッド | ＤＵＸ４の発現を低減するためのｐ３８阻害剤の使用 |
| WO2020263191A1 (en) * | 2019-06-27 | 2020-12-30 | Nanyang Technological University | Compounds having antimalarial activity |
| WO2021101854A1 (en) | 2019-11-19 | 2021-05-27 | Trevena, Inc. | Compounds and methods of preparing compounds s1p1 modulators |
| CN115490646A (zh) * | 2022-10-10 | 2022-12-20 | 安徽昊帆生物有限公司 | 3-硝基-1，2，4-三氮唑的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5283753A (en) * | 1976-01-01 | 1977-07-12 | Fuji Photo Film Co Ltd | Benzotriazole |
| US5716972A (en) | 1993-01-13 | 1998-02-10 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
| ATE186551T1 (de) | 1993-09-17 | 1999-11-15 | Smithkline Beecham Corp | Medikamente bindendes protein |
| US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
| ES2205167T3 (es) * | 1996-01-11 | 2004-05-01 | Smithkline Beecham Corporation | Nuevos compuestos de imidazol sustituidos. |
| GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| CA2333157A1 (en) | 1998-05-26 | 1999-12-02 | Smithkline Beecham Corporation | Novel substituted imidazole compounds |
| US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| US6350744B1 (en) | 1998-11-20 | 2002-02-26 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
| CA2355075C (en) | 1998-12-16 | 2009-12-08 | Aventis Pharma Limited | Heteroaryl-cyclic acetals |
| US6469018B1 (en) | 1999-01-08 | 2002-10-22 | Smithkline Beecham Corporation | Compounds |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
-
2002
- 2002-03-26 AT AT02252153T patent/ATE304009T1/de not_active IP Right Cessation
- 2002-03-26 ES ES02252153T patent/ES2247271T3/es not_active Expired - Lifetime
- 2002-03-26 EP EP02252153A patent/EP1247810B1/de not_active Expired - Lifetime
- 2002-03-26 DE DE60205974T patent/DE60205974T2/de not_active Expired - Fee Related
- 2002-04-02 CA CA002379903A patent/CA2379903C/en not_active Expired - Fee Related
- 2002-04-04 MX MXPA02003454A patent/MXPA02003454A/es active IP Right Grant
- 2002-04-04 US US10/115,952 patent/US6664395B2/en not_active Expired - Fee Related
- 2002-04-04 JP JP2002102969A patent/JP3832646B2/ja not_active Expired - Fee Related
- 2002-04-04 BR BR0201087-9A patent/BR0201087A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2247271T3 (es) | 2006-03-01 |
| US6664395B2 (en) | 2003-12-16 |
| JP2002308872A (ja) | 2002-10-23 |
| BR0201087A (pt) | 2003-05-27 |
| DE60205974D1 (de) | 2005-10-13 |
| JP3832646B2 (ja) | 2006-10-11 |
| CA2379903A1 (en) | 2002-10-04 |
| MXPA02003454A (es) | 2004-07-16 |
| US20030078432A1 (en) | 2003-04-24 |
| DE60205974T2 (de) | 2006-06-29 |
| EP1247810A1 (de) | 2002-10-09 |
| CA2379903C (en) | 2006-08-01 |
| EP1247810B1 (de) | 2005-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE304009T1 (de) | Neue benzotriazole mit entzündungshemmender wirkung | |
| DE69912823D1 (de) | Benzamid-derivate und ihre verwendung als cytokine inhibitoren | |
| ATE337312T1 (de) | Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen | |
| BR9812527A (pt) | Inibidores de benzenossulfonamida de pde-iv e seu uso terapêutico | |
| DE60316013D1 (de) | Heteroaryl-pyrimidinderivate als jak-inhibitoren | |
| WO2002085909A8 (en) | 9-deazaguanine derivatives as inhibitors of gsk-3 | |
| WO2020140005A3 (en) | 1 h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases | |
| CY1107433T1 (el) | Παραγωγα 1-(2η-πυραζολ-3-υλο)-3-(4-[1-(βενζοϋλο)-πιπepιδιν-4-υλομεθυλο]-φαινυλο)-ουριας και συναφεις ενωσεις ως αναστολεις της ρ38 κινασης και/ή tnf-αναστολεις για την αντιμετωπιση φλεγμονων | |
| NO20040511L (no) | Aminoisoxazolderivater som kinaseinhibitorer | |
| DK0529568T3 (da) | Nye oralt aktive elastaseinhibitorer | |
| BRPI9912726B8 (pt) | derivado de amida, composição farmacêutica, e, uso de um derivado de amida. | |
| NO995006L (no) | Nye forbindelser | |
| PT1311285E (pt) | Composicao farmaceutica liquida contendo um derivado de eritropoietina | |
| TR200102967T2 (tr) | Substitüsyonlu azollar | |
| NZ332240A (en) | Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) and are therefor useful for treating inflammatory diseases | |
| NO984199D0 (no) | Nye N-7-heterocyklylpyrrolo[2,3-D]pyridiner og deres anvendelse | |
| DE60232510D1 (de) | 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer | |
| NO20021448D0 (no) | Nye tiazolo (4,5-D)-pyrimidinforbindelser | |
| EA200501516A1 (ru) | Производные 2,3,6-тризамещённого-4-пиримидона | |
| DK0585155T3 (da) | Trifluormethylketon-peptidderivater med HLE-inhiberende aktivitet, deres fremstilling og farmaceutiske præparater | |
| DK0519327T3 (da) | N-Acyl-S-(2-hydroxyalkyl) -cysteiner, deres fremstilling samt deres anvendelse som mellemprodukter til fremstilling af synt | |
| NO308248B1 (no) | Forbindelser som er anvendbare som antiproliferative midler og GARFT-inhibitorer, samt farmasøytisk preparat | |
| PL358666A1 (en) | 2-hydroxy-mutilin carbamate derivatives for antibacterial use | |
| ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
| ATE389655T1 (de) | Pyrimidinderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |